Category Archives: PFE

Pfizer (PFE) 24Q2 Update

Posted on August 20, 2024 by Stephen Percoco

Pfizer (PFE) reported 24Q2 revenues of $13.3 billion, up 4% from 23Q2, but 4.5% below my estimate.  The shortfall from projections was due mostly to lower than expected sales of Comirnaty, Prevnar, Paxlovid and Abrysvo.  Pfizer’s GAAP EPS was $0.01, … Continue reading →

Posted in Health Care, PFE | Tagged , , | Leave a comment

Pfizer (PFE) 24Q1 Update

Posted on June 20, 2024 by Stephen Percoco

Pfizer (PFE) reported 24Q1 revenues of $14.9 billion, down 19% from 23Q1, but 7% above my estimate.  Its GAAP EPS was $0.55 and non-GAAP EPS $0.82, down from $0.97 and $1.23 last year, but well ahead of my estimates of … Continue reading →

Posted in Health Care, PFE | Tagged | Comments Off on Pfizer (PFE) 24Q1 Update

Initiating Coverage of Pfizer (PFE)

Posted on April 8, 2024 by Stephen Percoco

Buy Rating. Price Target of $30. As the COVID-19 pandemic receded, Pfizer’s sales and profits fell sharply.  Combined sales and alliance revenues of COMIRNATY, the COVID vaccine, and PAXLOVID, the COVID oral antiviral, fell 78% to $12.5 billion in 2023.  … Continue reading →

Posted in Health Care, PFE | Tagged , | Comments Off on Initiating Coverage of Pfizer (PFE)